AI Stock Memo: JSPR - Jasper Therapeutics - RankAlpha

JSPR

AI Memo

Jasper Therapeutics

As of 2026-07-04/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Protocol refiling and dose selection support operational progress in CSU • 2026-10-31

Expected move: -26%

Biggest risk

The same company-source record makes clear that study start timing depends on additional funding, so financing risk can override clinical progress for equity holders at the current stage [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The primary-source record supports constructive clinical positioning for briquilimab in CSU, with management highlighting positive January data, dose selection progress, and protocol refiling ahead of a planned Phase 2b study [#SEC-8K-2026-05-14].

Research note

Recommendation

—

Confidence

medium

As of

2026-07-04

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing is still the gating variable for the next CSU study step
Actual start of the planned Phase 2b/3 CSU study remains the core rerating hook
The primary-source record supports constructive clinical positioning for briquilimab in CSU, with management highlighting positive January data, dose selection progress, and protocol refiling ahead of a planned Phase 2b study [#SEC-8K-2026-05-14].

BearKey bullets

As a low-coverage micro-cap biotech, Jasper faces elevated volatility and thin external validation if milestones slip or financing terms are punitive.
Clinical execution risk remains meaningful despite improved data, especially around successful transition from prior studies into the planned Phase 2b/3 CSU program [#SEC-8K-2026-03-30].
Near-term financing and runway risk remain central because management linked Phase 2b commencement to securing additional funding [#SEC-8K-2026-05-14].

WatchKey bullets

Protocol refiling and dose selection support operational progress in CSU

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=45%)

Bull/Bear spread: +48% / -67%

Vs latest close: Bull +48% · Base -26% · Bear -67%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $0 (p=45%)Bear Target: $0 (p=30%)

Commentary

Tone is modestly constructive because primary company sources support protocol progress and prior CSU data strength, but this remains a cautious monitoring setup rather than a high-conviction thesis. Coverage is thin, recent trusted-news flow is sparse, no usable social-context packet was provided, and the main debate is still whether Jasper can finance the next study step on acceptable terms.

As of 2026-07-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Financing is still the gating variable for the next CSU study step
Actual start of the planned Phase 2b/3 CSU study remains the core rerating hook

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$0 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-07-13

Nearest Scenario: Base (∆ 26%)

Targets vs latest close: Bull +48% · Base -26% · Bear -67%

Sentiment & Exposure

News Sentiment (30d)

58.00

Social Sentiment (7d)

50.00

Events

Other notable items detected

EVENT2026-10-31
Protocol refiling and dose selection support operational progress in CSU
Management said it analyzed BEACON, SPOTLIGHT, and open-label extension data, selected two active dosing regimens for Phase 2b, and refiled the updated protocol with the FDA, which modestly de-risks execution but does not remove the funding dependency [#SEC-8K-2026-05-14].
Prob 60.00% • Move 18.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Financing is still the gating variable for the next CSU study step
2026-09-30
Jasper said it is working to secure additional funding to enable commencement of the planned Phase 2b CSU study in 2H26, while cash was $14.1 million at March 31, 2026 and quarterly R&D plus G&A expense totaled $10.9 million [#SEC-8K-2026-05-14].
Prob 75% • Move -30% • Priced-in 70%

Long-term Catalysts

Months to a year

Actual start of the planned Phase 2b/3 CSU study remains the core rerating hook
2026-12-31
The main upside catalyst is commencement of the planned Phase 2b/3 CSU study in the second half of 2026, but management tied that timeline to capital availability [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].
Prob 45% • Move 55% • Priced-in 25%

Risks

As a low-coverage micro-cap biotech, Jasper faces elevated volatility and thin external validation if milestones slip or financing terms are punitive.
Clinical execution risk remains meaningful despite improved data, especially around successful transition from prior studies into the planned Phase 2b/3 CSU program [#SEC-8K-2026-03-30].
Near-term financing and runway risk remain central because management linked Phase 2b commencement to securing additional funding [#SEC-8K-2026-05-14].

Peers

Symbol	Summary
AKTX	Loose micro-cap biotech peer; useful mainly for financing sensitivity and event-driven volatility, not for indication-level read-through.
KPRX	Another small-cap biotech comp where capital access and milestone timing can dominate equity value; operating comparability to Jasper is limited.
PHIO	Primarily a micro-cap biotech volatility comp rather than a close therapeutic peer; relevance is mostly around binary catalyst behavior.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-04